Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
This article has shown you how tirzepatide works and its many benefits
Effects of exenatide (Exendin-4) on glycemic control over 30 Weeks in sulfonylurea-treated patients with type 2 diabetes
Specifically, CeA Glp1r neurons are well-positioned to receive endogenous and exogenous GLP1 input and modulate VTA activity, thereby linking metabolic signals to dopamine-dependent reward circuits 3,46,47,48,49
US$ 20.41
US$ 26.22
US$ 22.13
US$ 27.32
US$ 28.79
US$ 27.66
US$ 21.15
US$ 26.10
US$ 27.75
US$ 24.28
US$ 21.19
.png)
US$ 21.36
US$ 20.88
US$ 24.70
